ACM
ZNTL icon

ADAR1 Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

ADAR1 Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$338K Buy
144,636
+64,636
+81% +$167K 0.02% 228
2025
Q4 		$108K Buy
80,000
+30,000
+60% +$43.7K 0.01% 249
2025
Q3 		$75.5K Hold
50,000
– – 0.01% 203
2025
Q2 		$58K Buy
+50,000
New +$65.9K 0.01% 188

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

ADAR1 Capital Management's ZNTL Position: Q1 2026 in Review

ADAR1 Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 81% in Q1 2026, buying an estimated $167K and bringing the position to 144,636 shares worth $338K. The position accounts for 0.02% of the portfolio, ranked #228.

ADAR1 Capital Management first reported a position in ZNTL in Q2 2025 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • ADAR1 Capital Management held 144,636 shares of Zentalis Pharmaceuticals worth $338K as of Q1 2026.
  • ADAR1 Capital Management bought 64,636 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $167K.
  • Zentalis Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #228 holding.
  • ADAR1 Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.